We are live on ! Find out more
AVM

Arch Venture Management Portfolio holdings

AUM $677M
1-Year Est. Return 322.07%
This Fund
S&P 500
This Quarter Est. Return
+37.1%
1 Year Est. Return
+322.07%
3 Year Est. Return
+208.96%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$652M
AUM Growth
+$159M
Cap. Flow
+$11M
Cap. Flow %
1.69%
Top 10 Hldgs %
100%
Holding
10
New
1
Increased
–
Reduced
–
Closed
1

Top Buys

Rank Stock Value
1
TXG icon
10x Genomics
TXG
+$11.1M

Top Sells

Rank Stock Value
1
CERO
CERo Therapeutics
CERO
+$114K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MAZE
1
Maze Therapeutics
MAZE
$1.55B
$171M 26.19%
4,120,053
– –
BEAM icon
2
Beam Therapeutics
BEAM
$2.65B
$126M 19.31%
4,540,132
– –
RAPP
3
Rapport Therapeutics
RAPP
$1.98B
$113M 17.36%
3,728,738
– –
LYEL icon
4
Lyell Immunopharma
LYEL
$315M
$84.9M 13.03%
2,759,072
– –
VIR icon
5
Vir Biotechnology
VIR
$1.52B
$77.9M 11.95%
12,916,663
– –
ERAS icon
6
Erasca
ERAS
$6.66B
$41.1M 6.31%
11,055,554
– –
GOSS icon
7
Gossamer Bio
GOSS
$68.7M
$25M 3.83%
8,055,916
– –
TXG icon
8
10x Genomics
TXG
$6.03B
$12M 1.85%
+737,539
New +$11.1M
QTTB icon
9
Q32 Bio
QTTB
$456M
$1.06M 0.16%
320,482
– –
CERO
10
DELISTED
CERo Therapeutics
CERO
– –
-22,389
Closed -$114K

Similar funds

NI
Noked Israel Ramat Hasharon, Israel $677M AUM 69.37% 1-Year Est. Return
MMPW
Mitchell McLeod Pugh & Williams Mobile, Alabama $678M AUM 23.02% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
NCM
Noesis Capital Mangement Boca Raton, Florida $676M AUM 34.17% 1-Year Est. Return
TWM
Topsail Wealth Management Charlotte, North Carolina $678M AUM 13.87% 1-Year Est. Return
DLIC
Daido Life Insurance Company Osaka, Japan $678M AUM 16.09% 1-Year Est. Return
REAM
Ripple Effect Asset Management New York $679M AUM 81.6% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

Arch Venture Management's Q4 2025 Portfolio in Review

As of Q4 2025, Arch Venture Management held 10 positions worth $652M, up 32% from $492M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Arch Venture Management's Q4 2025 filing shows 1 new and 1 closed positions. Its largest new stake was 10x Genomics: 737,539 shares worth $12M. The largest sale was CERo Therapeutics, an estimated $114K.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Arch Venture Management's largest Q4 2025 buy was 10x Genomics: 737,539 shares worth $12M.
  • Arch Venture Management fully exited CERo Therapeutics in Q4 2025, selling an estimated $114K.
  • Arch Venture Management's ten largest holdings make up 100% of its $652M portfolio in Q4 2025.
  • Arch Venture Management opened 1 new position and closed 1 in Q4 2025.
  • Arch Venture Management's portfolio value rose 32% quarter-over-quarter to $652M.

Based on Arch Venture Management's 13F filing for Q4 2025, filed 17 Feb 2026.